RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $70

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $81 to $70.